Senator Calls on Federal Health Authorities to Review China’s Role in US Drug Trials

Sen. Rick Scott flags Bioheng, a China-based company conducting clinical trials in the United States.

Soha Natour runs COVID-19 tests on samples received in the lab at Roseland Community Hospital in Chicago on Dec. 18, 2020.Scott Olson/Getty Images

Senate Committee on Aging Chairman Rick Scott (R-Fla.) is calling for immediate action from federal health agencies over Chinese entities participating in U.S. clinical trials and drug approval processes.

In a March 19 letter to federal health authorities, shared with The Epoch Times, Scott pointed to Bioheng, a China-based clinical-stage company also known as Imviva, as being “reportedly financed by [Chinese Communist Party-linked] sources.”